Sunpointe LLC Purchases New Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Sunpointe LLC purchased a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 443 shares of the medical equipment provider’s stock, valued at approximately $218,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Ullmann Wealth Partners Group LLC boosted its holdings in shares of Intuitive Surgical by 1.6% during the 3rd quarter. Ullmann Wealth Partners Group LLC now owns 1,329 shares of the medical equipment provider’s stock worth $653,000 after purchasing an additional 21 shares during the last quarter. One Wealth Management Investment & Advisory Services LLC raised its position in Intuitive Surgical by 3.4% in the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock valued at $310,000 after purchasing an additional 23 shares during the period. Daymark Wealth Partners LLC raised its position in Intuitive Surgical by 0.3% in the third quarter. Daymark Wealth Partners LLC now owns 7,027 shares of the medical equipment provider’s stock valued at $3,452,000 after purchasing an additional 24 shares during the period. Indiana Trust & Investment Management CO increased its position in shares of Intuitive Surgical by 5.3% during the second quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock worth $222,000 after acquiring an additional 25 shares during the period. Finally, Hoxton Planning & Management LLC increased its position in shares of Intuitive Surgical by 4.9% during the second quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock worth $238,000 after acquiring an additional 25 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ISRG shares. Redburn Atlantic raised Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $380.00 to $510.00 in a research report on Friday, August 2nd. Morgan Stanley increased their target price on Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Citigroup increased their target price on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. BTIG Research upped their price objective on shares of Intuitive Surgical from $494.00 to $518.00 and gave the company a “buy” rating in a research note on Monday. Finally, Piper Sandler upped their price objective on shares of Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a research note on Friday, July 19th. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $467.55.

Insider Transactions at Intuitive Surgical

In other news, Director Craig H. Barratt sold 1,400 shares of the firm’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total transaction of $641,382.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Craig H. Barratt sold 1,400 shares of the firm’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total transaction of $641,382.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the sale, the senior vice president now owns 3,001 shares in the company, valued at approximately $1,461,006.84. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 53,120 shares of company stock valued at $25,528,753 in the last ninety days. Corporate insiders own 0.90% of the company’s stock.

Intuitive Surgical Price Performance

Intuitive Surgical stock traded down $1.15 during mid-day trading on Wednesday, reaching $477.32. The company had a trading volume of 116,653 shares, compared to its average volume of 1,458,418. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $496.48. The company has a market capitalization of $169.31 billion, a P/E ratio of 86.37, a P/E/G ratio of 5.40 and a beta of 1.39. The stock’s 50-day simple moving average is $481.94 and its 200-day simple moving average is $436.37.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same period last year, the company posted $1.18 EPS. The company’s revenue was up 14.5% on a year-over-year basis. On average, equities analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.